Microbial Cell (Jun 2018)
Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms
- Patrick Van Dijck,
- Jelmer Sjollema,
- Bruno P.A. Cammue,
- Katrien Lagrou,
- Judith Berman,
- Christophe d’Enfert,
- David R. Andes,
- Maiken C. Arendrup,
- Axel A. Brakhage,
- Richard Calderone,
- Emilia Cantón,
- Tom Coenye,
- Paul Cos,
- Leah E. Cowen,
- Mira Edgerton,
- Ana Espinel-Ingroff,
- Scott G. Filler,
- Mahmoud Ghannoum,
- Neil A.R. Gow,
- Hubertus Haas,
- Mary Ann Jabra-Rizk,
- Elizabeth M. Johnson,
- Shawn R. Lockhart,
- Jose L. Lopez-Ribot,
- Johan Maertens,
- Carol A. Munro,
- Jeniel E. Nett,
- Clarissa J. Nobile,
- Michael A. Pfaller,
- Gordon Ramage,
- Dominique Sanglard,
- Maurizio Sanguinetti,
- Isabel Spriet,
- Paul E. Verweij,
- Adilia Warris,
- Joost Wauters,
- Michael R. Yeaman,
- Sebastian A.J. Zaat,
- Karin Thevissen
Affiliations
- Patrick Van Dijck
- VIB-KU Leuven Center for Microbiology, Leuven, Belgium.
- Jelmer Sjollema
- University of Groningen, University Medical Center Groningen, Department of BioMedical Engineering, Groningen, The Netherlands.
- Bruno P.A. Cammue
- Centre for Microbial and Plant Genetics, KU Leuven, Leuven, Belgium.
- Katrien Lagrou
- Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
- Judith Berman
- School of Molecular Cell Biology and Biotechnology, Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, Israel.
- Christophe d’Enfert
- Institut Pasteur, INRA, Unité Biologie et Pathogénicité Fongiques, Paris, France.
- David R. Andes
- Department of Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Maiken C. Arendrup
- Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark.
- Axel A. Brakhage
- Leibniz Institute for Natural Product Research and Infection Biology – Hans Knoell Institute (HKI), Dept. Microbiology and Molecular Biology, Friedrich Schiller University Jena, Institute of Microbiology, Jena, Germany.
- Richard Calderone
- Department of Microbiology & Immunology, Georgetown University Medical Center, Washington DC, USA.
- Emilia Cantón
- Severe Infection Research Group: Medical Research Institute La Fe (IISLaFe), Valencia, Spain.
- Tom Coenye
- Laboratory of Pharmaceutical Microbiology, Ghent University, Ghent, Belgium.
- Paul Cos
- Laboratory for Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Belgium.
- Leah E. Cowen
- Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
- Mira Edgerton
- Department of Oral Biology, School of Dental Medicine, University at Buffalo, Buffalo, NY USA.
- Ana Espinel-Ingroff
- VCU Medical Center, Richmond, VA, USA.
- Scott G. Filler
- Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
- Mahmoud Ghannoum
- Center for Medical Mycology, Department of Dermatology, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, USA.
- Neil A.R. Gow
- MRC Centre for Medical Mycology, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
- Hubertus Haas
- Biocenter – Division of Molecular Biology, Medical University Innsbruck, Innsbruck, Austria.
- Mary Ann Jabra-Rizk
- Department of Oncology and Diagnostic Sciences, School of Dentistry; Department of Microbiology and Immunology, School of Medicine, University of Maryland, Baltimore, USA.
- Elizabeth M. Johnson
- National Infection Service, Public Health England, Mycology Reference Laboratory, Bristol, UK.
- Shawn R. Lockhart
- Centers for Disease Control and Prevention, Atlanta, GA, USA.
- Jose L. Lopez-Ribot
- Department of Biology, South Texas Center for Emerging Infectious Diseases, The University of Texas at San Antonio, San Antonio, USA.
- Johan Maertens
- Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium and Clinical Department of Haematology, UZ Leuven, Leuven, Belgium.
- Carol A. Munro
- MRC Centre for Medical Mycology, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK.
- Jeniel E. Nett
- University of Wisconsin-Madison, Departments of Medicine and Medical Microbiology & Immunology, Madison, WI, USA.
- Clarissa J. Nobile
- Department of Molecular and Cell Biology, School of Natural Sciences, University of California, Merced, Merced, USA.
- Michael A. Pfaller
- Departments of Pathology and Epidemiology, University of Iowa, Iowa, USA.
- Gordon Ramage
- ESCMID Study Group for Biofilms, Switzerland.
- Dominique Sanglard
- Institute of Microbiology, University of Lausanne and University Hospital, CH-1011 Lausanne.
- Maurizio Sanguinetti
- Institute of Microbiology, Università Cattolica del Sacro Cuore, IRCCS-Fondazione Policlinico “Agostino Gemelli”, Rome, Italy.
- Isabel Spriet
- Pharmacy Dpt, University Hospitals Leuven and Clinical Pharmacology and Pharmacotherapy, Dpt. of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium.
- Paul E. Verweij
- Center of Expertise in Mycology Radboudumc/CWZ, Radboud University Medical Center, Nijmegen, the Netherlands (omit “Nijmegen” in Radboud University Medical Center).
- Adilia Warris
- MRC Centre for Medical Mycology, Aberdeen Fungal Group, University of Aberdeen, Foresterhill, Aberdeen, UK.
- Joost Wauters
- KU Leuven-University of Leuven, University Hospitals Leuven, Department of General Internal Medicine, Herestraat 49, B-3000 Leuven, Belgium.
- Michael R. Yeaman
- Geffen School of Medicine at the University of California, Los Angeles, Divisions of Molecular Medicine & Infectious Diseases, Harbor-UCLA Medical Center, LABioMed at Harbor-UCLA Medical Center.
- Sebastian A.J. Zaat
- Department of Medical Microbiology, Amsterdam Infection and Immunity Institute, Academic Medical Center, University of Amsterdam, Netherlands.
- Karin Thevissen
- Centre for Microbial and Plant Genetics, KU Leuven, Leuven, Belgium.
- DOI
- https://doi.org/10.15698/mic2018.07.638
- Journal volume & issue
-
Vol. 5,
no. 7
pp. 300 – 326
Abstract
Tuberculosis produces two clinical manifestations: active and latent (non-apparent) disease. The latter is estimated to affect one-third of the world population and constitutes a source of continued transmission should the disease emerge from its hidden state (reactivation). Methods to diagnose latent TB have been evolving and aim to detect the disease in people who are truly infected with M. tuberculosis, versus those where other mycobacteria, or even other pathologies not related to TB, are present. The current use of proteomic and transcriptomic approaches may lead to improved detection methods in the coming years.
Keywords
